Sign In
Buy UNCY
$7.20
-0.0300 (-0.415%)
At Close: Jun 03, 2026
Unicycive Therapeutics: A Catalyst Play With Real Fundamental Upside
02:54am, Thursday, 21'st May 2026
Unicycive Therapeutics is valued at $8/share, with $2/share in cash and the pipeline—primarily OLC—valued at $6/share. OLC targets hyperphosphatemia by reducing pill burden, aiming for improved pa
Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
07:05am, Tuesday, 12'th May 2026
MOUNTAIN VIEW, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, toda
Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
04:51pm, Thursday, 16'th Apr 2026
Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm
11:53am, Thursday, 09'th Apr 2026
NEW YORK, April 9, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) breac
Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
07:05am, Thursday, 09'th Apr 2026
LOS ALTOS, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the �
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
07:05am, Monday, 30'th Mar 2026
LOS ALTOS, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Receives Consensus Rating of “Moderate Buy” from Analysts
04:28am, Monday, 16'th Mar 2026
Unicycive Therapeutics, Inc. (NASDAQ: UNCY - Get Free Report) has earned an average recommendation of "Moderate Buy" from the five analysts that are covering the stock, Marketbeat.com reports. One res
Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm
11:59am, Friday, 06'th Mar 2026
New York, New York--(Newsfile Corp. - March 6, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Unicycive Therapeutics, Inc. (NASD
Philadelphia, Pennsylvania--(Newsfile Corp. - February 17, 2026) - WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY)
Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit
07:05am, Wednesday, 04'th Feb 2026
LOS ALTOS, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “C
Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile
04:09pm, Thursday, 29'th Jan 2026
I initiate Unicycive Therapeutics with a "Buy" rating, driven by the FDA's acceptance of its OLC NDA resubmission and a defined PDUFA date. OLC targets hyperphosphatemia in CKD dialysis patients, offe
UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
09:15am, Thursday, 29'th Jan 2026
FDA assigns Prescription Drug User Fee Act (PDUFA) target date of June 29, 2026 Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027 LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
07:05am, Thursday, 29'th Jan 2026
LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies fo
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)
07:05am, Monday, 29'th Dec 2025
New PDUFA date expected in 1H 2026 within 30 days of NDA resubmission New PDUFA date expected in 1H 2026 within 30 days of NDA resubmission
Philadelphia, Pennsylvania--(Newsfile Corp. - December 1, 2025) - Grabar Law Office is investigating claims on behalf of shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). The investigation
